Comparing the current results to its competitors, Plus Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by -70.43 %, despite the revenue increase by the most of its competitors of 29.28 %, recorded in the same quarter.
Plus Therapeutics Inc 's Comment on Competition and Industry Peers
The company anticipates that its product candidates, including rhenium (186 Re) obisbemeda and 188 RNL-BAM, will compete based on factors such as efficacy, safety, time to market, price, reimbursement, side effects, and treatment convenience. Competition may arise from single or combination therapies. Numerous organizations are engaged in drug development for similar indications. Notable competitors with drug development programs or clinical trials include EnGeneIC, Berg, Istari, AstraZeneca, Novartis, PharmAbcine, Kairos, Midatech, Oncovir, Infuseon, Astellas, NanoPharmaceuticals, Erasca, OX2, Crimson BioPharm, TMUNITY, Pfizer, Arcus, Photolitec, Samus, DNAtrix, ImmVira, BerGenBio, Boston Scientific, BeiGene, GSK, Bristol Myers Squibb, Eli Lilly, Sumitomo, QED, Chimerix, Accenda, Oblato, VBI, INIGHTEC, Sonalasense, VBL, Medicenna, Mimiva, Gilead, CNS Pharmaceuticals, and VAXIM. For the CNSide Test, competitors include Belay Diagnostics, BillionToOne, FYR Diagnostics, Cerevention, Genomic Testing Cooperative, Predicine, Neogenomics, Quest, and LabCorp.
August 12, 2024
Leptomeningeal metastases (LM) represent a significant challenge in oncology, often impacting prognosis and treatment outcomes. Recent presentations at the 2024 Society for Neuro-Oncology (SNO) and American Society of Clinical Oncology (ASCO) conference unveiled encouraging interim results from the ReSPECT-LM Phase 1 clinical trial conducted by Plus Therapeutics. This article discusses the findings and their potential implications for future therapeutic strategies. Leptomeningeal metastases occur when cancer cells spread to the cerebrospinal fluid (CSF) and surrounding membranes, creating substantial clinical challenges, including neurological deficits and poor prognosis. Standard treatment options are l...
July 2, 2024
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of CancerPlus Therapeutics, a leading pharmaceutical company focused on developing innovative therapies for the management of cancer, is thrilled to announce their participation in the prestigious Gordon Research Conference on Radionuclide Theranostics for the Management of Cancer. The conference, which will take place from date to date, brings together prominent scientists, clinicians, industry experts, and key stakeholders in the field of radiopharmaceuticals and nuclear medicine.The Gordon Research Conference provides a platform for researchers to share cutting-edge advancements, therapeutic approac...
March 25, 2024
The diagnosis and treatment of leptomeningeal metastasis, a devastating complication of adenocarcinoma and melanoma, is often challenging due to the limited tools available for accurate identification of cancer cells in the leptomeninges. In a recent breakthrough, Plus Therapeutics has announced the successful validation and clinical implementation of a novel diagnostic test called CSF-01, which promises to revolutionize the detection and monitoring of leptomeningeal cancer cells. This article aims to delve into the significance of this ground-breaking development in the field of oncology.Background and Significance:Leptomeningeal metastasis refers to the dissemination of cancer cells to the membrane envelop...
March 11, 2024
Plus Therapeutics, a leading pharmaceutical company, has successfully achieved a significant milestone in its groundbreaking clinical trial investigating the efficacy of Rhenium (186Re) Obisbemeda for the treatment of Leptomeningeal Metastases (LM). Following the completion of dosing in Cohort 5, a total of 18 patients have been enrolled in the trial so far, marking an important step towards evaluating the therapeutic potential of this novel drug.Leptomeningeal metastases, a devastating complication of cancer, occur when cancer cells spread to the membranes surrounding the brain and spinal cord. This condition poses a significant challenge for oncologists, as traditional treatments often fail to effectively ...
Perspective Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative therapeutic solutions. Their business model involves conducting extensive research and development to create novel drug candidates targeting specific diseases. They aim to collaborate with pharmaceutical companies and seek partnerships to further develop and commercialize their products, ultimately making a positive impact on patients' lives.
Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Mediwound Ltd operates through the development, manufacturing, and commercialization of biopharmaceutical products. Their business model primarily involves leveraging their expertise in biotechnology to create innovative therapies for the treatment of severe burns, chronic wounds, and other healing disorders.
Sources:
Plus Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Plus Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
